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(57) ABSTRACT 
Disclosed herein are methods and materials for influencing 
proliferation of stem cells. Specifically exemplified herein are 
compositions comprising cerium oxide nanoparticles which 
can be used to stimulate proliferation of stem cells under 
common culture conditions, or which can be utilized to 
improve therapeutic outcomes. 
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1 
METHODS AND MATERIALS FOR 
STIMULATING PROLIFERATION OF STEM 
CELLS 
RELATED APPLICATIONS 
This is a division of U.S. Ser. No. 11/968,393, filed Jan. 2, 
2008 now abandoned, and also claims priority to U.S. Ser. No. 
60/883,081, filed Jan. 2, 2007, which is incorporated herein 
by reference in its entirely. 
BACKGROUND OF THE INVENTION 
2 
cavity fluidly connected to a target tissue. In certain preferred 
embodiments, the body cavity is a brain ventricle. In other 
embodiments, the stem cells are inserted using a syringe or 
catheter, or surgically implanted directly at the target tissue 
site. In other embodiments, the stem cells are administered 
parenterally. Parenteral administration is historically defined 
as administration via a route that bypasses the gastrointestinal 
tract. Therefore, technically parenteral administration 
includes intraventricular administration, but intraventricular 
10 administration is typically discussed herein as separate from 
other modes of administration that may fall under 'parenteral 
administration'. 
Patients currently suffering from neurodegenerative con-
ditions such as Alzheimer's and Parkinson's have limited 15 
The compositions can be administered alone or in combi-
nation with at least one other agent, such as stabilizing or 
buffer compounds, which can be administered in any sterile, 
biocompatible pharmaceutical carrier, including, but not lim-treatment options. Conventional drug therapy helps delay or 
reduce the symptoms of disease but is unable to restore com-
plete functionality of the brain or repair damaged tissue. 
Through stem cell-based therapies, scientists aim to trans-
plant cells in order to regenerate damaged tissue and restore 
proper function. In addition to addressing neurodegenerative 
diseases, stem cell based therapies show much promise in 
addressing a vast number of other diseases, injuries and con-
ditions. The discovery of safe and inexpensive compositions 
to modulate stem cell proliferation would be a beneficial 
advancement in the filed of stem cell-based therapies and 
basic research. 
DETAILED DESCRIPTION 
Scientists are beginning to realize the potential power of 
stem-cell based therapies. It is widely recognized that stem 
cell transplantation may lead to treatments and/or cures of 
baneful disease states, degeneration and/or injury. The ability 
ited to, saline, buffered saline, dextrose, and water. In addition 
to the critical components of compositions discussed herein, 
cells or influencing factors, the compositions can contain 
20 suitable pharmaceutically acceptable carriers comprising 
excipients and auxiliaries which facilitate processing of the 
active compounds into preparations which can be used phar-
maceutically. Generally compositions can be administered by 
any number of routes including, but not limited to, oral, 
25 intravenous, intramuscular, intra-arterial, intramedullary, 
intrathecal, intraventricular, transdermal, subcutaneous, 
intraperitoneal, intranasal, parenteral, topical, sublingual, or 
rectal means. Factors can be administered at the same loca-
tion as administered stem cells. Administration of influencing 
30 factors and stem cells can be conducted simultaneously, or 
one prior to the other, and at the same or different locations so 
long as the relative locations allow for the factors to influence 
the stem cells. 
to stimulate the proliferation of stem cells in vivo or in vitro 35 
will be of tremendous benefit. The subject invention is based 
The administration of cerium oxide nanoparticles to stem 
cells can be conducted in vivo, ex vivo, in situ, and/or in vitro. 
According to a specific embodiment, cerium oxide nanopar-
ticles are applied to stem cells in vitro. This will aid and 
facilitate basic experiments conducted on stem cells that will 
benefit from stimulation of the stem cells or to create for the 
on the inventors discovery that certain nanoparticles can 
affect the proliferation of stem cells. 
stem cells an environment where oxidants are minimized. In 
other embodiments, the invention is directed to the stem cell 
proliferating cerium oxide nanoparticle compositions them-
selves. 
In other embodiments, the environment of administered 
stem cells is modified by administration of a separate popu-
lation of stem cells that are engineered to express influencing 
factors. Engineered stem cells designed to express influenc-
ing factors may be produced according to previously dis-
closed methods. See for example U.S. Patent Publication 
Nos. 20060134789 and 20060110440. According to a spe-
cific method embodiment, a population of therapeutic stem 
cells are administered to a locus of a subject's body and a 
population of engineered stem cells is administered at or 
proximate to the therapeutic population. Influencing factors 
In one embodiment, the subject invention pertains to a 
method of improving therapeutic outcomes of implanted 40 
stem cells comprising administering a Cerium Oxide (Ce02 ) 
nanoparticle composition in conjunction with stem cell 
implantation. The administration of the Cerium Oxide com-
position can be at or proximate to a target stem cell implan-
tation site in a human or nonhuman animal. In an alternative 45 
embodiment, the environment may be further modified by 
provision of influencing factors or by cleaning the environ-
ment of undesired or toxic agents that may affect adminis-
tered stem cells in an undesired way. The administered stem 
cells may be unmodified or may themselves be engineered to 50 
be biased toward a target differentiation endpoint. U.S. Patent 
Publication Nos. 20060134789 and 20060110440 are incor-
porated by reference to provide examples of stem cells engi-
neered for negative and positive differentiation biasing that 
are contemplated for use with the methods taught herein. 55 are expressed and released from the engineered stem cells 
which in tum influence the therapeutic stem cells for a desired 
objective. 
In another embodiment, the subject invention involves the 
administration of a composition comprising a administering 
Cerium Oxide nanoparticle composition to a body and 
administering stem cells to said body. The composition is 
administered at a locus in said body so as to allow contact with 
the stem cells. This may be at the same location, proximate to 
the location or distal to the location of where stem cells are 
administered. 
Stem cells may be administered by injecting one or a plu-
rality of stem cells with a syringe, inserting the stem cells with 
a catheter or surgically implanting the stem cells. In certain 
embodiments, the stem cells are administered into a body 
Thus, the invention also provides improved methods of 
treating health conditions implementing a stem cell strategy. 
60 For example, the methods taught herein may be used to treat 
or ameliorate symptoms due to a corporal or neurological 
(affecting nervous system), such as a deficit caused by a 
neurodegenerative disease, a traumatic injury, a neurotoxic 
injury, ischemia, a developmental disorder, a disorder affect-
65 ing vision, an injury or disease of the spinal cord, a demyeli-
nating disease, an autoimmune disease, an infection, an 
inflammatory disease, or corporal disease, disorder, injury, 
US 8, 772,032 B2 
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would recognize as being of interest or value in the particular 
context in which that discussion is presented. For example, it 
is often possible to substitute one buffer system or culture 
medium for another, such that a different but known way is 
used to achieve the same goals as those to which the use of a 
suggested method, material or composition is directed. 
trauma, malfunction, degeneration or loss. See, for example, 
U.S. Patent Publication No. 20030139410. In preferred 
embodiments, implanted stem cells are capable of proliferat-
ing, migrating to an area of tissue damage, and/or differenti-
ating in a tissue-specific manner and functioning in a manner 
that reduces the neurological or corporal deficit. Stem cells 
may be administered by injection with a syringe, inserting 
cells with a catheter or surgically implanting cells. In certain 
embodiments, stem cells are injected with a syringe into a 
body cavity that is fluidly-connected to the area of neurologi-
cal or corporal deficit. In certain preferred embodiments, the 
body cavity is a brain ventricle. In other embodiments, stem 
cells are inserted with a catheter into a body cavity that is 
fluidly-connected to the area of neurological or corporal defi-
cit. In certain preferred embodiments, the body cavity is a 
brain ventricle. In still further additional embodiments, stem 
cells are surgically implanted into a body cavity that is flu-
idly-connected to the area of neurological or corporal deficit. 
It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein, 
unless defined herein, are intended to have the same meaning 
10 as commonly understood by one of ordinary skill in the art. 
The techniques employed herein are also those that are known 
to one of ordinary skill in the art, unless stated otherwise. For 
purposes of more clearly facilitating an understanding the 
15 
invention as disclosed and claimed herein, the following defi-
In certain preferred embodiments, the body cavity is a brain 
ventricle. Stem cells can also alternatively be inserted using a 20 
syringe or catheter or surgically implanted directly at the site 
of the neurological or corporal deficit or systemically (e.g., 
intravenously). 
The invention provides methods of delivery and transplan-
tation of stem cells to ameliorate the effects of age, physical 25 
and biological trauma and degenerative disease on the brain 
or central nervous system of a human or nonhuman animal, as 
well as other tissues such as, for example, retinal tissue. It is 
well recognized in the art that transplantation of tissue into the 
CNS offers the potential for treatment of neurodegenerative 30 
disorders and CNS damage due to injury. Transplantation of 
new cells into the damaged CNS has the potential to repair 
damaged circuitries and provide neurotransmitters thereby 
restoring neurological function. It is also recognized in the art 
that transplantation into other tissue, such as eye tissue, offers 35 
the potential for treatment of degenerative disorders and tis-
sue damage due to injury. As disclosed herein, the invention 
provides methods for methods of modifying a tissue environ-
ment to influence proliferation, migration and differentiation 
of administered stem cells when introduced into a target site. 40 
In a certain specific embodiments, target sites may be those 
appropriate for treatment of neurological disorders and CNS 
damage. 
Recipients of administered stem cells can be immunosup-
pressed, either through the use of immunosuppressive drugs 45 
such as cyclosporin, or through local immunosuppression 
strategies employing locally applied immunosuppressants, 
but such immunosuppression need not necessarily be a pre-
requisite in certain immunoprivileged tissues such as, for 
example, brain and eye tissues. In certain embodiments, the 50 
delivery method of the invention can cause less localized 
tissue damage to the site of cell damage or malfunction than 
existing methods of delivery. 
In certain embodiments, administered stem cells are 
autologous in nature, i.e., prepared from the recipient's own 55 
tissue. In such instances, the progeny of stem cells can be 
generated from dissociated or isolated tissue and proliferated 
in vitro using known methods. In the case of mesenchymal 
stem cells (MeSCs), progeny can be generated from MeSCs 
isolated from, for example, bone marrow. Upon suitable 60 
expansion of cell numbers, the stem cells of the invention can 
nitions are provided. 
EXAMPLE 1 
Preparation of Cerium Oxide Nanoparticles 
Cerium oxide nanoparticles of a size approximately 2 nm 
to approximately 10 nm in diameter, are prepared by a process 
including the steps of dissolving approximately 0.5 grams to 
approximately 1.0 grams of Ce(N03 ) 3 .6H2 0 in deionized 
water to make approximately 10 mis of solution to form a first 
solution, followed by dissolving approximately 3 grams to 
approximately 4 grams of AOT (surfactant) in approximately 
200 ml of solvent to form a second solution, followed by 
combining the first and the second solutions, followed by 
stirring the combined solutions for approximately 30 min-
utes, and drop wise adding approximately 30% hydrogen 
peroxide (H20 2 ) until the stirred combined solution becomes 
yellow, and subsequently stirring for approximately 30 min-
utes to approximately 60 minutes more. Thus, aqueous 
reverse micelles (RMs) are surfactant aggregates in nonpolar 
solvents that enclose packets of aqueous solution in their 
interior. The size of the water droplet can be tuned by varying 
the ratio of water to surfactant. RMs used as reaction media in 
the production of nanoparticles whose size and shape are 
controlled by water and surfactant ratio. The surfactant is 
stripped off using simple washing and drying. Size: 3-5 nm. 
EXAMPLE2 
The synthesis of ceria was carried out by direct synthesis 
route from the cerium precursor (Ce(N03 ) 3 .6H20) dissolved 
in water. Oxidation of cerium nitrate was carried out using 
hydrogen peroxide (H20 2 ). It is a very simple one step pro-
cess yielding ceria nanoparticles dispersed in water (a very 
useful delivery media for biological studies). The process 
leads to formation of cerium oxide nanoparticles of 15-20 nm 
particle size (agglomerates) consisting 3-5 nm spherical crys-
tals. 
EXAMPLE3 
Particles may be obtained via heating of the particles in 
produced in Example 1 above, anywhere between 100-400 C. 
EXAMPLE4 
be harvested and readied for administration into the recipi-
ent's affected tissue. 
Reference to particular buffers, media, reagents, cells, cul-
ture conditions and the like, or to some subclass of same, is 
not intended to be limiting, but should be read to include all 
such related materials that one of ordinary skill in the art 
Cerium oxide particles are obtained from commercially 
available sources. Particles are dried from the slurry, washed 
65 in water and redispersed in the water at a certain pH. Without 
being bound to any particular theory, it is believed that the 
variation in the stem cell proliferation, though not yet shown 
US 8, 772,032 B2 
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to be statistically significant, appears to be attributable to 
difference in the Ce+3/Ce+4 ratio in the samples. 
EXAMPLES 
Stimulation of Stem Cell Proliferation 
6 
of cell proliferation had a marked increase. Though all 
samples showed an influence on proliferation, Sample 3, 
which is composed ofCe02 nanoparticles 10-20 nm in size 
and spherically shaped and showed highest increase, 
increased mesenchymal stem cell proliferation rates by as 
much as 50%. 
While a number of embodiments of the present invention 
have been shown and described herein in the present context, 
such embodiments are provided by way of example only, and 
10 not of limitation. Numerous variations, changes and substi-
tutions will occur to those of skilled in the art without mate-
rially departing from the invention herein. It should be borne 
in mind that all patents, patent applications, patent publica-
tions, technical publications, scientific publications, and 
Stem cell growth and division rates can be increased by 
lowering the oxidative stress on the cells. We propose using 
this method to increase the proliferation rates of stem cells 
under common culture conditions. Specifically, we can 
improve stem cell proliferation rates by as much as 50%. 
Furthermore, we propose that this method can be used to 
enable the growth of stem cells for emergency tissue repair as 
well as for therapeutic use. This therapy can be used in con-
junction with currently available drugs and biologics with 
little concern over negative interactions and helps eliminate 
the possibility for graft-verse-host disease. Using five differ-
ent samples of cerium oxide, Ce02, nanoparticles, size and 
shape, 3-5 nm spherical, 11-15 nm agglomerates of 3-5 nm 20 
individual crystals, 10-20 nm spherical, 7-10 nm spherical, 
and 10-20 nm cuboidal, the inventors found a good working 
concentration by making serial dilutions of each sample, then 
applied each for a plated dish of rat mesenchymal stem cells, 
also known as adult stem cells. Although a wide range of 25 
concentrations can be used, the inventors found that 10 nM 
appeared to be an optimal concentration. When rat and human 
mesenchymal stem cells were plated at known densities, 
treated with one of the Ce02 samples, allowed to grow for 
periods of 24, 48, and 72 hours, then performed a cell count 
for each of the samples and the control untreated cells, the rate 
15 other references referenced herein are hereby incorporated by 
reference in this application, in their entirety to the extent not 
inconsistent with the teachings herein. 
What is claimed is: 
1. A method of stimulating proliferation of a population of 
stem cells, said method comprising contacting said popula-
tion with cerium oxide nanoparticles in vitro, wherein said 
nanoparticles are spherical in shape and are about 10-20 nm in 
size and are provided in a culture media at a concentration to 
promote proliferation of said stem cells; and 
culturing said population of stem cells in said culture 
media under conditions and time period to increase the 
population of stem cells. 
2. The method of claim 1, wherein said stem cells are 
mesenchymal stem cells. 
* * * * * 
